{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:26:48Z","timestamp":1790468808220,"version":"4.1.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.3816\/clm.2007.s.021","type":"journal-article","created":{"date-parts":[[2008,9,18]],"date-time":"2008-09-18T01:01:38Z","timestamp":1221699698000},"page":"S184-S191","source":"Crossref","is-referenced-by-count":11,"special_numbering":"S5","title":["Expanding Therapeutic Options in Mantle Cell Lymphoma"],"prefix":"10.3816","volume":"7","author":[{"given":"Andre","family":"Goy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyanna","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2007.s.021_bib1","first-page":"11","article-title":"Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives","volume":"91","author":"Salaverria","year":"2006","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2007.s.021_bib2","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1073\/pnas.0510441103","article-title":"Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma","volume":"103","author":"Greiner","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLM.2007.s.021_bib3","first-page":"8226","article-title":"The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival","volume":"63","author":"Martinez","year":"2003","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2007.s.021_bib4","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1182\/blood-2002-11-3456","article-title":"Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations","volume":"101","author":"Camacho","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.021_bib5","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1182\/blood-2003-05-1632","article-title":"Mantle cell lymphoma with t(11;14) and unmutated or mutated VH genes expresses AID and undergoes isotype switch events","volume":"103","author":"Babbage","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.021_bib6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/labinvest.3780061","article-title":"Development of intermediate-grade (mantle cell) and low-grade (small lymphocytic and marginal zone) human non-Hodgkin's lymphomas xenotransplanted in severe combined immunodeficiency mouse models","volume":"80","author":"Bryant","year":"2000","journal-title":"Lab Invest"},{"key":"10.3816\/CLM.2007.s.021_bib7","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1182\/blood-2005-10-4042","article-title":"Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas","volume":"107","author":"Fu","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.021_bib8","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2141.2005.05630.x","article-title":"Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways","volume":"130","author":"Rizzatti","year":"2005","journal-title":"Br J Haematol"},{"issue":"suppl 6","key":"10.3816\/CLM.2007.s.021_bib9","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/annonc\/7.suppl_6.S35","article-title":"Mantle-cell lymphoma: classification and therapeutic implications","volume":"7","author":"Fisher","year":"1996","journal-title":"Ann Oncol"},{"issue":"suppl 8","key":"10.3816\/CLM.2007.s.021_bib10","first-page":"49","article-title":"Management of mantle cell lymphoma","volume":"12","author":"Armitage","year":"1998","journal-title":"Oncology (Williston Park)"},{"key":"10.3816\/CLM.2007.s.021_bib11","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1182\/blood.V89.6.2067","article-title":"Mantle cell lymphoma: a clinicopathologic study of 80 cases","volume":"89","author":"Argatoff","year":"1997","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.021_bib12","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/cncr.11096","article-title":"Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma","volume":"97","author":"Romaguera","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CLM.2007.s.021_bib13","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/modpathol.3880448","article-title":"Leukemic mantle cell lymphoma: clinical and pathologic spectrum of twenty-three cases","volume":"14","author":"Schlette","year":"2001","journal-title":"Mod Pathol"},{"key":"10.3816\/CLM.2007.s.021_bib14","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus highdose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.3816\/CLM.2007.s.021_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/11.suppl_1.S123","article-title":"The effect of rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK)","volume":"11","author":"Ghielmini","year":"2000","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib16","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib17","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and high- dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib18","doi-asserted-by":"crossref","first-page":"30a","DOI":"10.1182\/blood.V104.11.1388.1388","article-title":"Phase II study of modified hyper- CVAD with rituximab maintenance for previously untreated mantle cell lymphoma: a Wisconsin Oncology Network Study","volume":"104","author":"Kahl","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.021_bib19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.1998.16.2.579","article-title":"Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas","volume":"16","author":"Decaudin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib20","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.1999.17.2.546","article-title":"Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma","volume":"17","author":"Foran","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib21","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3109\/10428190109097721","article-title":"Cyclophosphamide\/fludarabine (CF) is active in the treatment of mantle cell lymphoma","volume":"42","author":"Cohen","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2007.s.021_bib22","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.021_bib23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1023\/A:1008325212484","article-title":"Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse","volume":"10","author":"Rummel","year":"1999","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib24","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0959-8049(02)00143-0","article-title":"Reduced-dose cladribine (2- CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma","volume":"38","author":"Rummel","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.3816\/CLM.2007.s.021_bib25","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/cncr.22196","article-title":"Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma","volume":"107","author":"Robak","year":"2006","journal-title":"Cancer"},{"key":"10.3816\/CLM.2007.s.021_bib26","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00001622-200403000-00004","article-title":"An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma","volume":"16","author":"Jacobsen","year":"2004","journal-title":"Curr Opin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib28","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/sj.bmt.1703255","article-title":"Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials?","volume":"28","author":"Sweetenham","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLM.2007.s.021_bib29","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","article-title":"Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study","volume":"16","author":"Lefrere","year":"2002","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2007.s.021_bib30","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","article-title":"High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma","volume":"99","author":"Gopal","year":"2002","journal-title":"Blood"},{"issue":"suppl 1","key":"10.3816\/CLM.2007.s.021_bib31","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/sj.bmt.1703296","article-title":"Rituximab: enhancing stem cell transplantation in mantle cell lymphoma","volume":"29","author":"Gianni","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLM.2007.s.021_bib32","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdi107","article-title":"Hematopoietic stem cell transplantation in mantle cell lymphoma","volume":"16","author":"Ganti","year":"2005","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/j.seminoncol.2003.12.008","article-title":"Clearing minimal residual disease with rituximab consolidation therapy","volume":"31","author":"Brugger","year":"2004","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib34","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.seminoncol.2003.12.002","article-title":"Integrating monoclonal antibodies into the management of mantle cell lymphoma","volume":"31","author":"Berinstein","year":"2004","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib35","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.3816\/CLM.2007.s.021_bib36","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2007.s.021_bib37","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib38","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib39","doi-asserted-by":"crossref","first-page":"175a","DOI":"10.1182\/blood.V104.11.608.608","article-title":"Phase II trial of bortezomib in mantle cell lymphoma","volume":"104","author":"Belch","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.021_bib40","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","article-title":"Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib41","doi-asserted-by":"crossref","first-page":"575s","DOI":"10.1200\/jco.2005.23.16_suppl.6563","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): preliminary results of the PINNACLE study","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib42","doi-asserted-by":"crossref","first-page":"425s","DOI":"10.1200\/jco.2006.24.18_suppl.7512","article-title":"Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): results of the PINNACLE study","volume":"24","author":"Goy","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib43","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib44","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","article-title":"The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status","volume":"107","author":"Perez-Galan","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.021_bib45","doi-asserted-by":"crossref","first-page":"456s","DOI":"10.1200\/jco.2007.25.18_suppl.8062","article-title":"A feasibility study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma","volume":"25","author":"Kahl","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib46","first-page":"147a","article-title":"Phase I\/II trial of bortezomib + CHOP-rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): phase I results","volume":"104","author":"Leonard","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.021_bib47","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/sj.leu.2404511","article-title":"Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma","volume":"21","author":"Weigert","year":"2007","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2007.s.021_bib48","doi-asserted-by":"crossref","first-page":"389a","DOI":"10.1182\/blood.V104.11.1387.1387","article-title":"Sensitivity, schedule-dependence and molecular effects of the proteasome inhibitor bortezomib in non-Hodgkin's lymphoma cells","volume":"104","author":"Goy","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.021_bib49","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/sj.bjc.6603406","article-title":"A novel proteasome inhibitor NPI-0052 as an anticancer therapy","volume":"95","author":"Chauhan","year":"2006","journal-title":"Br J Cancer"},{"key":"10.3816\/CLM.2007.s.021_bib50","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1365-2141.2007.06504.x","article-title":"The proteasome inhibitors bortezomib and PR171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells","volume":"136","author":"Stapnes","year":"2007","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2007.s.021_bib51","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimuns (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib52","doi-asserted-by":"crossref","first-page":"430s","DOI":"10.1200\/jco.2006.24.18_suppl.7532","article-title":"Anti-tumor activity of mTOR inhibitor remsirolimus for relapsed mantle cell lymphoma: A phase II trial in the North Central Cancer Treatment Group","volume":"24","author":"Ansell","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib53","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.021_bib54","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","article-title":"Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies","volume":"12","author":"Yee","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2007.s.021_bib55","doi-asserted-by":"crossref","first-page":"592s","DOI":"10.1200\/jco.2005.23.16_suppl.6631","article-title":"A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies","volume":"23","author":"Feldman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib56","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-03-1091","article-title":"Antitumor activity of rituximab plus thalidomide in patients with relapsed\/refractory mantle cell lymphoma","volume":"104","author":"Kaufmann","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.021_bib57","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2141.2004.05239.x","article-title":"Proapoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab","volume":"127","author":"Ramanarayanan","year":"2004","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2007.s.021_bib58","doi-asserted-by":"crossref","first-page":"7697","DOI":"10.1200\/JCO.2005.02.4364","article-title":"Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia","volume":"23","author":"O'Brien","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib59","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1158\/1078-0432.CCR-05-0308","article-title":"The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide","volume":"12","author":"O'Connor","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2007.s.021_bib60","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.blre.2004.11.002","article-title":"Bcl-2 antisense therapy in B-cell malignancies","volume":"19","author":"Chanan-Khan","year":"2005","journal-title":"Blood Rev"},{"key":"10.3816\/CLM.2007.s.021_bib61","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.surg.2006.03.014","article-title":"Bcl-XL antisense oligonucleotides coupled with antennapedia enhances radiation-induced apoptosis in pancreatic cancer","volume":"140","author":"Masui","year":"2006","journal-title":"Surgery"},{"key":"10.3816\/CLM.2007.s.021_bib62","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","article-title":"The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently indoses apoptosis via Bak\/Bax if Mcl-1 is neutralized","volume":"10","author":"van Delft","year":"2006","journal-title":"Cancer Cell"},{"key":"10.3816\/CLM.2007.s.021_bib63","first-page":"429a","article-title":"The small molecule pan-Bcl-2 inhibitor GX15-070 induces apoptosis in vitro in mantle cell lymphoma (MCL) cells and exhibits a synergistic effect in combination with the proteasome inhibitor bortezomib","volume":"106","author":"Perez Galan","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.021_bib64","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/91000","article-title":"Tumoricidal activity of a novel antihuman DR5 monoclonal antibody without hepatocyte cytotoxicity","volume":"7","author":"Ichikawa","year":"2001","journal-title":"Nat Med"},{"key":"10.3816\/CLM.2007.s.021_bib65","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.021_bib66","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","article-title":"Outcomes after alemtuzumabcontaining reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma","volume":"104","author":"Morris","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.021_bib67","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1053\/sonc.2003.50057","article-title":"CD22 as a target of passive immunotherapy","volume":"30","author":"Cesano","year":"2003","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib68","doi-asserted-by":"crossref","first-page":"71a","DOI":"10.1182\/blood.V106.11.230.230","article-title":"Preliminary report of a phase I study of CMC-544, an antibody-targeted chemotherapy agent, in patients with B-cell non-Hodgkin's lymphoma (NHL)","volume":"106","author":"Advani","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.021_bib69","doi-asserted-by":"crossref","first-page":"425a","DOI":"10.1182\/blood.V106.11.1473.1473","article-title":"Targeting CD20 and CD22 with rituximab in combination with CMC-544 results in improved anti-tumor activity against non-Hodgkin's lymphoma (NHL) pre-clinical models","volume":"106","author":"Hernandez-Ilizaliturri","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.021_bib70","doi-asserted-by":"crossref","first-page":"433a","DOI":"10.1182\/blood.V106.11.1504.1504","article-title":"A phase I study of humanized anti-CD40 immunotherapy with SGN-40 in non-Hodgkin's lymphoma","volume":"106","author":"Advani","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.021_bib71","doi-asserted-by":"crossref","first-page":"146a","DOI":"10.1182\/blood.V106.11.489.489","article-title":"Results of a Phase II trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed\/refractory non-Hodgkin's lymphoma (NHL)","volume":"106","author":"Younes","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.021_bib72","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/nm1290","article-title":"Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma","volume":"11","author":"Neelapu","year":"2005","journal-title":"Nat Med"},{"key":"10.3816\/CLM.2007.s.021_bib73","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1200\/JCO.2003.05.501","article-title":"Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma","volume":"21","author":"Khouri","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib74","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma","volume":"104","author":"Maris","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.021_bib75","doi-asserted-by":"crossref","first-page":"720a","DOI":"10.1182\/blood.V104.11.2632.2632","article-title":"A phase II study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin\u00ae) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL)","volume":"104","author":"Oki","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.021_bib76","doi-asserted-by":"crossref","first-page":"430s","DOI":"10.1200\/jco.2006.24.18_suppl.7533","article-title":"Efficacy of radioimmunotherapy with (90Y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: results of two phase II trials of the European MCL Network and the PLRG","volume":"24","author":"Weigert","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib77","first-page":"406a","article-title":"Initial treatment of mantle cell lymphoma with sequential radioimmunotherapy with tositumomab\/iodine I131 I-tositumomab followed by CHOP chemotherapy results in a high complete remission rate","volume":"102","author":"Zelenetz","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.021_bib78","doi-asserted-by":"crossref","first-page":"422s","DOI":"10.1200\/jco.2006.24.18_suppl.7503","article-title":"Phase II study of rituximab + CHOP followed by 90Y-ibritumomab tiuxetan in patents with previously untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1499)","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib79","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/jco.2003.09.057","article-title":"Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group","volume":"21","author":"Kouroukis","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib80","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/10428190290016908","article-title":"Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma","volume":"43","author":"Lin","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2007.s.021_bib81","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1158\/1078-0432.CCR-05-0831","article-title":"Chronic lymphocytic leukemia: a niche for flavopiridol?","volume":"11","author":"Brown","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2007.s.021_bib82","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","article-title":"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia","volume":"109","author":"Byrd","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.021_bib83","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","article-title":"Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies","volume":"24","author":"O'Connor","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.021_bib84","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0609.2005.00546.x","article-title":"Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma","volume":"76","author":"Heider","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2007.s.021_bib85","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","article-title":"Inhibition of constitutive NFkappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis","volume":"171","author":"Pham","year":"2003","journal-title":"J Immunol"},{"key":"10.3816\/CLM.2007.s.021_bib86","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1158\/1078-0432.28.11.1","article-title":"Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling","volume":"11","author":"Lam","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2007.s.021_bib87","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1158\/1078-0432.2.11.1","article-title":"From microarray to bedside: targeting NFkappaB for therapy of lymphomas","volume":"11","author":"Rabson","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2007.s.021_bib88","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/modpathol.3880562","article-title":"Real-time RT-PCR assay for quantifying cyclin D1 mRNA in B-cell non-Hodgkin's lymphomas","volume":"15","author":"Medeiros","year":"2002","journal-title":"Mod Pathol"},{"key":"10.3816\/CLM.2007.s.021_bib89","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"10.3816\/CLM.2007.s.021_bib90","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1200\/JCO.2005.05.019","article-title":"Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways","volume":"23","author":"Fernandez","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011701354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011701354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T00:04:35Z","timestamp":1684541075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011701354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":90,"alternative-id":["S1557919011701354"],"URL":"https:\/\/doi.org\/10.3816\/clm.2007.s.021","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}